0000950170-24-042381.txt : 20240405
0000950170-24-042381.hdr.sgml : 20240405
20240405200006
ACCESSION NUMBER: 0000950170-24-042381
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240403
FILED AS OF DATE: 20240405
DATE AS OF CHANGE: 20240405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moran Kyle
CENTRAL INDEX KEY: 0001657765
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37627
FILM NUMBER: 24827857
MAIL ADDRESS:
STREET 1: C/O WAVE LIFE SCIENCES LTD.
STREET 2: 733 CONCORD AVE.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Wave Life Sciences Ltd.
CENTRAL INDEX KEY: 0001631574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 STRAITS VIEW
STREET 2: #12-00, MARINA ONE EAST TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 018936
BUSINESS PHONE: 617-949-2900
MAIL ADDRESS:
STREET 1: 733 CONCORD AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
FORMER COMPANY:
FORMER CONFORMED NAME: WAVE Life Sciences Ltd.
DATE OF NAME CHANGE: 20170516
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences Ltd.
DATE OF NAME CHANGE: 20151106
FORMER COMPANY:
FORMER CONFORMED NAME: Wave Life Sciences LTD.
DATE OF NAME CHANGE: 20151106
4
1
ownership.xml
4
X0508
4
2024-04-03
0001631574
Wave Life Sciences Ltd.
WVE
0001657765
Moran Kyle
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
CAMBRIDGE
MA
02138
false
true
false
false
Chief Financial Officer
true
Ordinary Shares
2024-04-03
4
S
false
15630
6.169
D
33921
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.115 to $6.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Includes 3,431 ordinary shares acquired on January 14, 2024, under the issuer's 2019 Employee Share Purchase Plan.
/s/ Kyle Moran
2024-04-05